Printer Friendly

Four anticonvulsants' link to suicide supported.

The link between anticonvulsant agents and suicidal acts or violent death--first revealed in a Food and Drug Administration meta-analysis in 2008--appears to have been confirmed for four of the drugs: gabapentin, lamotrigine, oxcarbazepine, and tiagabine, according to a report in JAMA.

In what investigators described as the first study to directly compare suicide risks with different anticonvulsants given in routine care, "increased risk for suicidal acts beginning within the first 14 days of treatment initiation" were found, reported Dr. Elisabetta Patorno of Brigham and Women's Hospital, Boston, and her associates. This finding opens the possibility that anticonvulsants "could induce [adverse] behavioral effects prior to the achievement of their full therapeutic effectiveness," they wrote.

The investigators noted that in the FDA meta-analysis, the number of events was small and largely confined to cases of suicidal ideation only. This "prevented definitive conclusions about the safety of individual agents."

In addition, in many of the studies included in the meta-analysis, the anticonvulsant agents were used as adjunctive treatment, "further complicating the assessment of their individual effect.

"Thus, the FDA meta-analysis could not provide patients or clinicians with clear guidelines on risk for specific agents or patient subgroups," Dr. Patorno and her colleagues noted.

They addressed these issues by conducting a cohort study using a database that included 297,620 new prescriptions for anticonvulsant drugs in 17 states between 2001 and 2006. The risk of attempted or completed suicidal acts or violent deaths were compared between patients aged 15 and older who had initiated treatment with one of two reference anticonvulsants (topiramate or carbamazepine) and patients who had initiated treatment with any of 13 other anticonvulsants.

The study subjects were to be followed for 180 days or until they discontinued or switched medications, had a study outcome, or discontinued the study for other reasons. Mean follow-up turned out to be 91 days. There were 801 attempted suicides, 26 completed suicides, and 41 violent deaths within 180 days of initiating anticonvulsant therapy.

Compared with subjects initiating use of topiramate or carbamazepine, those starting on gabapentin, lamotrigine, oxcarbazepine, and tiagabine were at significantly increased risk for these events, the investigators said (JAMA 2010;303:1401-9).

A further analysis of the data showed that new users of gabapentin had an excess of 5.6 cases of attempted or completed suicide per 1,000 person-years, new users of oxcarbazepine had an excess of 10 cases per 1,000 person-years, and new users of tiagabine had an excess of 14.1 cases per 1,000 person-years, compared with new users of topiramate.

This study was funded by the Health-Core Fellowship in Pharmacoepidemiology and the Pharmacoepidemiology Research and Training Fund of the Harvard School of Public Health. Dr. Patorno reported no financial conflicts of interest.
COPYRIGHT 2010 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Moon, Mary Ann
Publication:Clinical Psychiatry News
Date:May 1, 2010
Words:455
Previous Article:Attitudes 'out of sync' on buprenorphine.
Next Article:FDA approves harder-to-abuse formulation of OxyContin.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters